2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

www.kumc.edu

 

Lung
17:19

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

The Use of IO Agents in Metastatic NSCLC: Overview of Anti-PD-1/Anti-PD-L1 Agents and Their Combinations, and Outcomes of Pivotal Trials

FEATURING Don Gibbons
  • 846 views
  • November 12, 2019
  • 1
10:16

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Immunotherapy in Advanced NSCLC: Difficulties With Biomarkers Development and Selection

FEATURING Don Gibbons
  • 89 views
  • November 12, 2019
13:33

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Checkpoint Inhibitors in Stage III NSCLC (Pacific Trial Regimen) / Biomarker Development and the Immune Landscape of Early Stage NSCLC

FEATURING Don Gibbons
  • 129 views
  • November 12, 2019
17:11

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Microbiome as a Predictive Ecosystem for Immunotherapy in NSCLC Can Potentially Predict Both Treatment Response and Adverse Effects

FEATURING Jun Zhang
  • 38 views
  • November 12, 2019
12:42

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

New KRAS G12C / MET Exon 14 TKI’s for Advanced NSCLC: Favorable Safety Profile and Promising Antitumor Activity of AMG 510 / Capmatinib and Bozitinib

FEATURING Chao Huang
  • 430 views
  • November 12, 2019
22:41

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

New TKI’s in Development for Lung Cancer. An Overview of New ROS1 / TRK / ALK / RET / EGFR Inhibitors, Clinical Trial Outcomes, Mechanisms of Resistance, and Safety Profiles

FEATURING Chao Huang
  • 338 views
  • November 12, 2019
  • 1